↓ Skip to main content

Endocannabinoids

Overview of attention for book
Attention for Chapter 15: Endocannabinoids
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (83rd percentile)
  • Good Attention Score compared to outputs of the same age and source (66th percentile)

Mentioned by

twitter
6 X users
facebook
5 Facebook pages
googleplus
1 Google+ user

Readers on

mendeley
61 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Endocannabinoids
Chapter number 15
Book title
Endocannabinoids
Published in
Handbook of experimental pharmacology, January 2015
DOI 10.1007/978-3-319-20825-1_15
Pubmed ID
Book ISBNs
978-3-31-920824-4, 978-3-31-920825-1
Authors

Izzo, Angelo A, Muccioli, Giulio G, Ruggieri, Michael R, Schicho, Rudolf, Angelo A. Izzo, Giulio G. Muccioli, Michael R. Ruggieri, Rudolf Schicho, Izzo, Angelo A., Muccioli, Giulio G., Ruggieri, Michael R.

Editors

Roger G. Pertwee

Abstract

Components of the so-called endocannabinoid system, i.e., cannabinoid receptors, endocannabinoids, as well as enzymes involved in endocannabinoid synthesis and degradation, have been identified both in the gastrointestinal and in the urinary tract. Evidence suggests that the endocannabinoid system is implicated in many gastrointestinal and urinary physiological and pathophysiological processes, including epithelial cell growth, inflammation, analgesia, and motor function. A pharmacological modulation of the endocannabinoid system might be beneficial for widespread diseases such as gastrointestinal reflux disease, irritable bowel syndrome, inflammatory bowel disease, colon cancer, cystitis, and hyperactive bladder. Drugs that inhibit endocannabinoid degradation and raise the level of endocannabinoids, non-psychotropic cannabinoids (notably cannabidiol), and palmitoylethanolamide, an acylethanolamide co-released with the endocannabinoid anandamide, are promising candidates for gastrointestinal and urinary diseases.

X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 2%
Canada 1 2%
Unknown 59 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 10 16%
Student > Ph. D. Student 8 13%
Student > Master 8 13%
Other 7 11%
Student > Bachelor 6 10%
Other 8 13%
Unknown 14 23%
Readers by discipline Count As %
Medicine and Dentistry 11 18%
Biochemistry, Genetics and Molecular Biology 7 11%
Pharmacology, Toxicology and Pharmaceutical Science 6 10%
Agricultural and Biological Sciences 5 8%
Psychology 4 7%
Other 9 15%
Unknown 19 31%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 August 2018.
All research outputs
#4,285,424
of 23,577,654 outputs
Outputs from Handbook of experimental pharmacology
#135
of 654 outputs
Outputs of similar age
#59,138
of 356,631 outputs
Outputs of similar age from Handbook of experimental pharmacology
#22
of 66 outputs
Altmetric has tracked 23,577,654 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 654 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.0. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 356,631 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 66 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.